MAY.12.14

In the News

SEPT.04.17

Though genetics has fundamentally changed the pace of drug development for many therapeutic areas, the brain has been slow to reveal its inner workings. A new generation of neuroscience-focused biotech companies is poised to change that paradigm.

JAN.09.17

Allergan swooped into JP Morgan bearing news of a pair of deals, inking an exclusive option to buy out Lysosomal Therapeutics for its neurodegeneration pipeline and paying $50 million upfront to partner with Assembly Bio on the microbiome.

JAN.09.17

Allergan today disclosed deals that will expand its gastrointestinal (GI) pipeline with four potential treatments focused on the microbiome, as well as broaden its R&D portfolio through an option to buy a drug developer focused on treating Parkinson’s disease.

JAN.09.17

Today Allergan announced a transformative deal with Lysosomal Therapeutics (LTI), an emerging biotech focused on Parkinson’s disease through an understanding of human genetics and sphingolipid biology.

JAN.09.17

Allergan now has the right to acquire Lysosomal Therapeutics, a Cambridge, MA-based drug developer for Parkinson’s disease seeking to exploit the link between neurodegeneration and a family of rare genetic disorders.

JUL.14.15

While the prevalence of neurodegenerative disorders, including Parkinson’s disease (PD), remains daunting, recent significant progress in defining the molecular causes of these diseases has provided novel drug targets.

JAN.03.15

Lysosomal Therapeutics of Cambridge, MA, has closed a $20 million Series A round to push forward a drug for Parkinson’s disease that exploits the link between neurodegeneration and a family of rare genetic disorders.

JAN.03.15

Cambridge biotech Lysosomal Therapeutics just raised a whopping $20 million Series A for its small molecule Parkinson’s disease treatment, with backing from the venture arms of several big pharma – Sanofi, Lilly and Roche.

JAN.15.15

When his company raised nearly $5 million in seed funding last year, Lysosomal Therapeutics founder, president, and CEO Kees Been said he had two goals: learn more about the underlying connection between the rare Gaucher disease and Parkinson’s disease, and sort through compounds licensed from the National Institutes of Health to find the best one to turn into a Parkinson’s drug.

MAY.26.14

Lysosomal Therapeutics is developing brain-penetrant small molecules for a genetically validated Parkinson's target that it believes will be disease-modifying for idiopathic PD and potentially other synucleinopathies.